WAM
ATXI

Warberg Asset Management’s Avenue Therapeutics, Inc. Common Stock ATXI Stock Holding History

Warberg Asset Management’s Portfolio ATXI Stock Details ATXI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-9
Closed -$9K – 258
2021
Q4 		$9K Buy
+9
New +$13K ﹤0.01% 192

Other funds holding ATXI

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BRWA
B. Riley Wealth Advisors Boca Raton, Florida $1.87B AUM 37.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TSS
Two Sigma Securities New York $861M AUM 21.33% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Warberg Asset Management's ATXI Position: Q1 2022 in Review

Warberg Asset Management sold out of Avenue Therapeutics, Inc. Common Stock (ATXI) in Q1 2022, closing a stake of 9 shares — an estimated $9K sold.

Warberg Asset Management first reported a position in ATXI in Q4 2021 and held it in 1 quarter. The position peaked at $9K in Q4 2021. 14 funds tracked by Wall St. Rank hold ATXI as of Q1 2022.

  • Warberg Asset Management reported no remaining Avenue Therapeutics, Inc. Common Stock position as of Q1 2022 after selling out during the quarter.
  • Warberg Asset Management sold 9 Avenue Therapeutics, Inc. Common Stock shares in Q1 2022, an estimated $9K.
  • Warberg Asset Management first reported a position in Avenue Therapeutics, Inc. Common Stock in Q4 2021 and held it in 1 quarter.
  • Warberg Asset Management's Avenue Therapeutics, Inc. Common Stock position peaked at $9K in Q4 2021.
  • 14 funds tracked by Wall St. Rank held Avenue Therapeutics, Inc. Common Stock as of Q1 2022.

Based on Warberg Asset Management's 13F filing for Q1 2022, filed 13 May 2022.